Investment Rating - The report assigns a "Buy" rating for the company for the first time [2]. Core Insights - The company has successfully transitioned from an agent-driven model to a self-research and brand-driven approach, enhancing its competitive edge [10]. - The company is focusing on five major product categories: home rehabilitation aids, medical care, health monitoring, respiratory support, and traditional Chinese medicine, which together cover over 65% of the home medical device market in China [6]. - The company aims for a compound annual growth rate (CAGR) of 16.96% in net profit from 2024 to 2026, reflecting confidence in achieving high-quality growth [6]. Financial Projections - Revenue projections are as follows: - 2023: 2,854 million CNY - 2024: 2,983 million CNY (5% growth) - 2025: 3,384 million CNY (13% growth) - 2026: 4,098 million CNY (21% growth) - 2027: 5,100 million CNY (24% growth) [2]. - Net profit projections are as follows: - 2023: 254 million CNY - 2024: 312 million CNY (23% growth) - 2025: 359 million CNY (15% growth) - 2026: 436 million CNY (22% growth) - 2027: 551 million CNY (26% growth) [2]. Market Position and Strategy - The company has established a strong channel advantage with over 700 self-operated stores and partnerships with more than 70 major pharmacy chains, ensuring extensive distribution across China [13]. - The company has a diversified product matrix with over 200 products covering various health management scenarios, focusing on high-margin core categories [16]. - The company is enhancing its product offerings through high-end brand collaborations, such as with Philips, and is investing in AI and brain-computer interface technologies to drive future growth [6][20]. Growth Drivers - The home rehabilitation aids market in China is projected to grow from 39 billion USD to 65 billion USD from 2020 to 2024, with the company holding a market share of approximately 2.4% [48]. - The health monitoring market is expected to reach 54 billion USD, with innovative products like dual-function blood sugar and uric acid monitors driving growth [6]. - The company’s international expansion strategy has seen its overseas revenue grow by over 200% year-on-year, increasing its contribution to total revenue from 2.0% in 2024 to 6.5% in 2025 [6]. Management and Governance - The company's management team is stable, with the founder holding a significant share of 54%, ensuring clear control and efficient decision-making [22]. - A new stock incentive plan has been introduced, binding management to high-quality growth targets for the next three years [26].

Investment Rating - The report assigns a "Buy" rating for the company, marking the first coverage of the stock [2]. Core Insights - The company has successfully transitioned from an agent-driven model to a self-research and brand-driven approach, enhancing its competitive edge in the home medical device market [10]. - The company is expected to achieve significant revenue growth, with projections of 33.84 billion, 40.98 billion, and 51.00 billion yuan for 2025, 2026, and 2027 respectively, reflecting year-on-year growth rates of 13%, 21%, and 24% [6][28]. - The company has established a strong channel advantage, with self-owned brand revenue accounting for 83.18% of total revenue as of the first half of 2025 [6][10]. Summary by Relevant Sections Company Overview - The company has over 20 years of experience in building a robust online and offline channel system, transitioning from agent-driven sales to a model that emphasizes self-research and multi-brand operations [6][10]. - The company has a diverse product matrix covering over 200 products, focusing on five key areas: rehabilitation aids, medical care, health monitoring, respiratory support, and traditional Chinese medicine [16][20]. Financial Performance - The company's revenue for 2023 is projected at 2,854 million yuan, with a year-on-year decline of 4%. However, revenue is expected to grow to 3,384 million yuan in 2025, reflecting a 13% increase [2]. - The net profit for 2023 is estimated at 254 million yuan, with a projected increase to 359 million yuan in 2025, representing a 15% growth [2]. Market Position and Strategy - The company holds a leading position in the home rehabilitation aids market, with a market share of approximately 2.4% in China, and is expected to benefit from the growing demand for home medical devices [6][48]. - The company has initiated a strategic focus on high-margin core products, with the gross margin expected to reach 51.86% in 2024, up from previous lows [32]. Growth Drivers - The company is expanding its international presence, with products already in over 60 countries and regions, and overseas revenue expected to grow significantly [6][20]. - The establishment of an AI research institute and strategic investments in brain-computer interface technology are expected to drive future growth and innovation [6][20]. Management and Governance - The company's management team is stable, with a concentrated ownership structure that supports efficient decision-making and long-term strategic execution [22][26]. - A new equity incentive plan has been introduced, linking management compensation to high-quality growth targets, further demonstrating management's confidence in the company's future performance [26].

Group 1: Business Performance and Strategy - The company aims to enhance the operational quality of existing stores, with a reported revenue growth of over 20% year-on-year in the first half of 2025 [2] - The company plans to launch new products and strengthen online and offline channel collaboration to expand its hearing business [2] - The overseas business achieved nearly 100 million in revenue, with a year-on-year growth exceeding 200% [4] Group 2: Investments and Acquisitions - The company invested in NeuLink Medical in May 2024 to explore advanced hearing rehabilitation solutions through brain-machine interface technology [3] - In January 2025, the company completed a controlling acquisition of Shanghai Huazhou, enhancing its product line and overseas market channels [4] - The company also acquired a controlling stake in Ximan Na in June 2025, facilitating entry into the Hong Kong market [4] Group 3: Online Sales and Market Trends - The company has developed a comprehensive product matrix covering five major areas, maintaining strong sales performance on mainstream e-commerce platforms [6] - Interest e-commerce platforms have gained popularity, prompting the company to invest in innovative content to enhance brand visibility and product sales [6] Group 4: AI and Technology Development - The company is advancing AI applications across various medical devices, focusing on interconnectivity and data exchange [7] - The upcoming Kefu Health APP will integrate data from multiple devices to provide personalized health management solutions [7] Group 5: Core Product Strategy - The company focuses on core product categories that contribute significantly to revenue and have growth potential, including respiratory machines and hearing aids [8] - Continuous improvement in product quality and market share is a priority, with plans for iterative upgrades and cost reductions [8] Group 6: Respiratory Device Performance - The company's self-developed respiratory machines have received high consumer recognition, with sales rapidly increasing since late June 2025 [9]

Group 1: Company Performance - The company achieved a revenue of 2.983 billion CNY in 2024, representing a year-on-year growth of 4.53% [7] - The net profit attributable to shareholders was 312 million CNY, with a year-on-year increase of 22.60% [7] - The net profit excluding non-recurring gains and losses was 275 million CNY, showing a growth of 36.74% [7] - The net cash flow from operating activities reached 663 million CNY, up by 68.45% [7] Group 2: Market and Product Development - The company has established three research institutes focusing on medical electronics, biomedicine, and respiratory support, enhancing its R&D capabilities [2] - The self-developed ventilator has received high consumer recognition, with plans to launch a new generation of products [3] - The hearing aid segment reported a revenue of 273 million CNY in 2024, a growth of 37.86%, despite a loss of 43.25 million CNY due to new store performance [4] Group 3: Strategic Initiatives - The company aims for high-quality, sustainable development through diversified marketing strategies during promotional events [5] - Future dividend policies will focus on stable returns to shareholders while ensuring sustainable company growth [6] - The company is leveraging the "Healthy China" strategy and the aging population trend to drive demand for home medical devices [8] Group 4: Industry Outlook - The medical device industry is expected to grow due to increased health awareness and technological advancements [9] - Companies with strong R&D and operational capabilities are likely to maintain competitiveness, while those with product homogeneity face challenges [9] - The company plans to enhance its core product innovation and expand its international market presence [9]